Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Publications and Abstracts

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events
Society for Neuro-Oncology Annual Meeting 2022

Society for Neuro-Oncology Annual Meeting 2022

Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM

Nov 18, 2022
Society for Neuro-Oncology Annual Meeting 2022

Society for Neuro-Oncology Annual Meeting 2022

Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report

Nov 18, 2022
Society for Neuro-Oncology Annual Meeting 2022

Society for Neuro-Oncology Annual Meeting 2022

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program

Nov 18, 2022
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

Dianhydrogalactitol (VAL-083) for the Treatment of Glioblastoma Multiforme (GBM): Impact of Glucose Transporters for Crossing the Blood Brain Barrier (BBB)

Apr 11, 2022
Society for Neuro-Oncology Annual Meeting 2021

Society for Neuro-Oncology Annual Meeting 2021

Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM

Nov 18, 2021
Society for Neuro-Oncology Annual Meeting 2021

Society for Neuro-Oncology Annual Meeting 2021

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab naïve glioblastoma in the adjuvant or recurrent setting

Nov 18, 2021
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting

Apr 10, 2021
American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly-diagnosed, MGMT-unmethylated glioblastoma

Apr 10, 2021

H.C. Wainwright Bioconnect 2021 Virtual Conference Presentation

Jan 11, 2021
Glioblastoma Drug Development Summit

Glioblastoma Drug Development Summit

Dec 10, 2020
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next »
© 2023 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences